2476859-56-8: Ticagrelor -3 Nitroso Impurity

Ticagrelor -3 Nitroso Impurity (CAS No.2476859-56-8) or N-((1R, 2S)-2-(3, 4-difluorophenyl)cyclopropyl)-N-(3-((3aS, 4R, 6S, 6aR)-6-(2-hydroxyethoxy)-2, 2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)-5-(propylthio)-3H-[1, 2, 3]triazolo[4, 5-d]pyrimidin-7-yl)nitrous amide,Ticagrelor is a P2Y12 receptor antagonist that lowers the risk of myocardial infarction and ischemic stroke by preventing the development of thrombi. Given twice daily, it has a modest duration of effect and a broad therapeutic index because of the tolerability of high single doses. The risks of bleeding, dyspnea, and bradyarrhythmias should be discussed with patients. Adenylyl cyclase is inhibited by the P2Y12 receptor’s coupling with Gi2 and other Gi proteins. Additionally, PI3K, Akt, Rap1b, and potassium channels are activated by 3 Gi signaling. These processes’ after-effects, mediate hemostasis and cause platelet aggregation.

Additional information

Catalogue No.

VE008628

CAS No.

2476859-56-8

Molecular Formula

C26H31F2N7O5S

Molecular Weight

591.6 g/mol

IUPAC Name

N-((1R, 2S)-2-(3, 4-difluorophenyl)cyclopropyl)-N-(3-((3aS, 4R, 6S, 6aR)-6-(2-hydroxyethoxy)-2, 2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)-5-(propylthio)-3H-[1, 2, 3]triazolo[4, 5-d]pyrimidin-7-yl)nitrous amide

References

Fuller, Raeanne, and Benjamin Chavez. “Ticagrelor (Brilinta), an Antiplatelet Drug for Acute Coronary Syndrome.” P & T : A Peer-Reviewed Journal for Formulary Management, vol. 37, no. 10, MediMedia USA, Inc., 2012, pp. 562–68, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474441/. ‌

Status

In-stock